MGTX - MeiraGTx Holdings plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.98
+0.55 (+2.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close23.43
Open23.40
Bid0.00 x 2200
Ask0.00 x 1100
Day's Range23.07 - 24.53
52 Week Range7.98 - 24.53
Volume169,812
Avg. Volume175,737
Market Cap799.556M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
Trade prices are not sourced from all markets
  • 3 Biotech Stocks That Soared Last Week: Are They Buys?
    Motley Fool3 days ago

    3 Biotech Stocks That Soared Last Week: Are They Buys?

    Can these high-flying biotech stocks keep the momentum going?

  • Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
    Investor's Business Daily5 days ago

    Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

    Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

  • GlobeNewswire8 days ago

    MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    • Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the.

  • GlobeNewswire8 days ago

    MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

    LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive data from a Phase 1/2 dose escalation trial of AAV-RPE65, the Company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability. The trial enrolled 15 patients, including nine young adults (aged 16-24 years old) across three dose escalation cohorts, and six children (aged 5-12 years old) in a pediatric expansion cohort.

  • GlobeNewswire12 days ago

    MeiraGTx Appoints Nicole Seligman to Board of Directors

    LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, legal, compliance and governance experience. “We are delighted to welcome Nicole to the MeiraGTx Board of Directors at this exciting time for the company,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

  • GlobeNewswire16 days ago

    MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference

    LONDON and NEW YORK, May 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,.

  • GlobeNewswire27 days ago

    MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019

    LONDON and NEW YORK, April 25, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster.

  • The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
    Zacks27 days ago

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

  • 5 Biotech Stocks Defying the Medicare-for-All Scare
    Zacks28 days ago

    5 Biotech Stocks Defying the Medicare-for-All Scare

    Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.

  • GlobeNewswire2 months ago

    MeiraGTx Reports Full Year 2018 Financial Results

    LONDON and NEW YORK, March 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • Barrons.com2 months ago

    Johnson & Johnson Buys Large Stake in MeiraGTx

    JNJ is now the third-largest shareholder in the gene-therapy firm after a $40 million investment. MeiraGTx stock has doubled so far this year.

  • 10 Stocks For The Gene Therapy Revolution
    Investopedia2 months ago

    10 Stocks For The Gene Therapy Revolution

    Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.

  • GlobeNewswire3 months ago

    MeiraGTx to Present at the Barclays Global Healthcare Conference

    LONDON and NEW YORK, March 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • Why NOW Is the Time to Buy Gene Therapy Stocks
    InvestorPlace3 months ago

    Why NOW Is the Time to Buy Gene Therapy Stocks

    The biotech industry has been on a tear in 2019, up 25% through the first two months of the year. That's great. But niche gene therapy stocks are performing even better.Source: Shutterstock The rally has been fueled by a strong combination of merger announcements, positive news from the FDA and the continued development of breakthrough therapies. Headlines have been popping up nonstop over the last week, and today I'd like to recap some of the highlights. Spark Therapeutics (NASDAQ:ONCE), a small-cap biotech that focuses on gene therapies, was purchased by pharmaceutical giant Roche (OTCMKTS:RHHBY). On a per-share basis, the $4.8 billion purchase price equated to $114.50 -- a huge 122% premium over ONCE's previous close. Spark investors are now looking at 190% gains in 2019 alone.The same day, CRISPR Therapeutics (NASDAQ:CRSP) announced that human trials had begun for its CTX001 gene therapy drug. A patient suffering from beta-thalassemia had been dosed. And in just a few months, the same drug is expected to be tested on patients with sickle cell disease.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCTX001, which is based on the CRISPR/Cas9 gene editing technique, is currently undergoing Phase I/II trials. Typically, the first dose in such a trial would not be a headline. But this was the first time that CRISPR technology had ever been used on a human. The news sent CRSP up more than 20%. * 7 Top-Rated Stocks to Buy for March A few days later, gene therapy stock Sarepta Therapeutics (NASDAQ:SRPT) released impressive results for its muscular dystrophy drug. And in the same press release it announced the $165 million purchase of privately-held gene therapy company Myonexus. The stock rallied on the news and is now up 34% so far this year. But even with the acquisition news, SRPT has long been rumored as a takeover target for larger pharmaceutical companies.Finally, micro-cap gene therapy stock MeiraGTx Holdings (NASDAQ:MGTX) announced an $80 million private placement. This is important because its lead investor is the private arm of Johnson & Johnson (NYSE:JNJ). MeiraGTx is already up a whopping 67% in 2019. Get in Position for Life-Changing Profits from Gene Therapy StocksThere is absolutely no question that there is money to be made in the gene therapy stocks over the long term. However, because the sector is still in its infancy, we have to expect increased volatility. What we're seeing now is a very strong upswing.Gene therapy is on track to save countless lives. It's also on track to make you life-changing profits as long as you can weather the ups and downs that are simply the nature of early-stage mega-trends.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever Compare Brokers The post Why NOW Is the Time to Buy Gene Therapy Stocks appeared first on InvestorPlace.

  • GlobeNewswire3 months ago

    MeiraGTx Announces $80 Million Private Placement of Ordinary Shares

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 5.8 million ordinary shares at a price of $13.80 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $80 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general purposes.

  • GlobeNewswire3 months ago

    MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors

    LONDON and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Board of Directors. Martin Indyk is an American diplomat who has served in senior positions in the U.S. presidential administrations of Clinton, Bush ’43 and Obama.

  • GlobeNewswire3 months ago

    MeiraGTx to Present at the BIO CEO & Investor Conference

    LONDON and NEW YORK, Feb. 05, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • GlobeNewswire4 months ago

    MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a broad strategic collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize gene therapies for the treatment of inherited retinal diseases (IRDs). Under the agreement, the two companies will collaborate in the clinical development of MeiraGTx’s leading IRD pipeline, including product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP).

  • PR Newswire4 months ago

    Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

    RARITAN, N.J. , Jan. 31, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: ...

  • Do Directors Own MeiraGTx Holdings plc (NASDAQ:MGTX) Shares?
    Simply Wall St.5 months ago

    Do Directors Own MeiraGTx Holdings plc (NASDAQ:MGTX) Shares?

    If you want to know who really controls MeiraGTx Holdings plc (NASDAQ:MGTX), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...

  • GlobeNewswire5 months ago

    MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference

    LONDON and NEW YORK, Jan. 02, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • GlobeNewswire5 months ago

    MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease

    LONDON and NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced publication of research assessing the mechanism underlying the motor improvement observed in patients with Parkinson’s disease who were treated with adeno-associated virus (AAV) encoding glutamic acid decarboxylase (AAV-GAD), an investigational gene therapy product candidate, in a completed Phase 2 study. In the new research, which was published in the November 28, 2018 issue of Science Translational Medicine, patients treated with AAV2-GAD gene therapy (in which glutamic acid decarboxylase [GAD] was delivered into the subthalamic nucleus [STN]) expressed a distinct treatment-related metabolic brain network, providing a clinical benefit by inducing the formation of new polysynaptic pathways connecting the STN to cortical motor regions.

  • GlobeNewswire6 months ago

    MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    LONDON and NEW YORK, Nov. 08, 2018 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for.

  • GlobeNewswire7 months ago

    MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia

    LONDON and NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH), an agency of the United States Department of Health & Human Services. Under the agreement, MeiraGTx will receive worldwide rights to adeno-associated virus vector mediated gene delivery of aquaporin-1, designated AAV-AQP1, for Sjögren’s syndrome patients with associated xerostomia (dry mouth) or xerophthalmia (dry eyes).